SENORES PHARMACEUTICALS L
SENORES · General/Diversified · NSE
₹1,111
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for SENORES yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
None
Confidence
22%
ROE
7.2%
Debt/Equity
0.39
WACC
11.1%
Market Cap
₹5,116 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
9.6%
Return on capital employed
EV / EBITDA
28.5×
Enterprise multiple
Debt / EBITDA
2.0×
Leverage vs earnings
Interest Coverage
4.5×
EBIT covers interest
Current Ratio
3.00×
Short-term liquidity
Asset Turnover
0.53×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
SENORES · last 4 annual periods
ROE
7.2%
ROCE
9.6%
Operating Margin
—
Debt / Equity
0.39×
PE
—
EV / EBITDA
—
Historical Financials
SENORES · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹14.1 Cr | ₹35.3 Cr | ₹211 Cr | ₹398 Cr | ₹633 Cr | +159.0% |
| EBITDA | ₹2.4 Cr | ₹16.1 Cr | ₹43.5 Cr | ₹109 Cr | ₹215 Cr | +209.1% |
| EBIT | ₹1.7 Cr | ₹14.3 Cr | ₹33.4 Cr | ₹90.9 Cr | — | +172.3% |
| PAT | ₹1.0 Cr | ₹8.4 Cr | ₹31.4 Cr | ₹58.6 Cr | ₹115 Cr | +228.5% |
| EPS (diluted) | ₹0.22 | ₹1.83 | ₹6.83 | ₹16.12 | — | +194.2% |
| CFO | ₹-10.4 Cr | ₹-1.1 Cr | ₹-25.7 Cr | ₹-45.9 Cr | ₹62.0 Cr | — |
| CapEx | ₹-10.7 Cr | ₹-47.3 Cr | ₹-51.8 Cr | ₹-158 Cr | ₹-265 Cr | — |
| FCF | ₹-21.1 Cr | ₹-48.4 Cr | ₹-77.5 Cr | ₹-203 Cr | ₹-203 Cr | — |
| Total Assets | ₹59.2 Cr | ₹131 Cr | ₹622 Cr | ₹1227 Cr | ₹1604 Cr | +128.2% |
| Total Debt | ₹14.8 Cr | ₹62.6 Cr | ₹258 Cr | ₹315 Cr | ₹342 Cr | +119.4% |
| Shareholders' Equity | ₹36.6 Cr | ₹45.5 Cr | ₹204 Cr | ₹786 Cr | ₹934 Cr | +124.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SENORES vs 4 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SMSPHARMA SMSPHARMA | — | — | Pending | 10.8% | — |
SAIPARENT SAIPARENT | — | — | Pending | 15.9% | — |
 NGLFINE NGLFINE | — | — | Pending | 14.6% | — |
 TTKHLTCARE TTKHLTCARE | — | — | Pending | 7.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SENORES in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of SENORES →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SENORES →
Compare
Head-to-head with peers
Compare SENORES side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SENORESNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.